BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $CADL readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07332000-pcd@datacutoff.com
DTSTAMP:20261118T142521Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~aglatimagene besadenovec + valacyclovir readout (P2) · Candel The
 rapeutics\, Inc. $CADL
DESCRIPTION:A Biomarker Study in Men With Localized Prostate Cancer Treated
  With Aglatimagene Besadenovec\n\nPrimary completion date: 2027-02 (estima
 ted) — month only\, shown on the 1st\nOriginally planned: 2026-06 (+8.0 
 months)\nPhase 2 · Oncology · Prostate Cancer Patients Treated by Radiot
 herapy\, Prostate Cancer (Adenocarcinoma)\nEnrollment: 45 · Sites: 7\n\nP
 rimary completion = last participant's primary-endpoint data collected\; t
 opline results usually follow weeks to months later. Sponsor-reported\, of
 ten an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT07332000\nhttps://clinicaltrials.gov/study/NCT07332000
URL:https://datacutoff.com/radar.html?nct=NCT07332000
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
